Published in Rev Med Liege on September 01, 1997
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord (1998) 1.76
Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab (2013) 1.64
The intrathymic expression of insulin-related genes: implications for pathophysiology and prevention of Type 1 diabetes. Diabetes Metab Rev (1998) 1.58
No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab (2000) 1.25
Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. J Clin Endocrinol Metab (1991) 1.15
Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab (1996) 1.12
Severe/extreme obesity: a medical disease requiring a surgical treatment? Acta Clin Belg (1999) 1.06
The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level. J Clin Endocrinol Metab (1996) 1.02
Factors controlling gastric-glucagon release. J Clin Invest (1977) 1.02
A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia (1983) 0.98
Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study. Fertil Steril (1986) 0.96
Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab (1994) 0.95
Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia (1986) 0.93
Metabolic control may influence the increased superoxide generation in diabetic serum. Diabet Med (1991) 0.92
How to measure insulin clearance. Diabetes Metab Rev (1994) 0.92
Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Diabetes Metab (2009) 0.91
Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab (1993) 0.89
Insulin action in man. Diabetes Metab (1996) 0.89
Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. Diabetologia (1996) 0.88
Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion. Diabetes Care (1984) 0.87
The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev (2004) 0.86
Effect of dog jejunum "glucagon-like immunoreactive material" on adipose tissue metabolism. Horm Metab Res (1969) 0.86
Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with type 1 diabetes. J Clin Endocrinol Metab (1988) 0.86
Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. Diabete Metab (1995) 0.85
A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia (1983) 0.84
Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med (1995) 0.84
Metabolic adaptations in post-exercise recovery. Clin Physiol (1982) 0.84
Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Saf (1995) 0.83
Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care (1991) 0.83
Oral antidiabetic agents. A guide to selection. Drugs (1998) 0.82
Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr (2000) 0.82
[Reactive hypoglycaemia, a mysterious, insidious but non dangerous critical phenomenon]. Rev Med Liege (2004) 0.82
Postgastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab (1995) 0.82
Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord (1994) 0.81
How to measure insulin action in vivo. Diabetes Metab Rev (1994) 0.81
[Etiopathogenesis and pathophysiology of type 2 diabetes]. Rev Med Liege (2005) 0.80
Inflammatory markers and cardiometabolic diseases. Acta Clin Belg (2015) 0.80
Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control. Diabet Med (2003) 0.80
From plant physiology to human metabolic investigations. Diabetologia (1985) 0.79
Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab (1999) 0.79
Endogenous substrate oxidation during exercise and variations in breath 13CO2/12CO2. J Appl Physiol (1985) (1993) 0.79
Opioid peptides and metabolic regulation. Diabetologia (1988) 0.79
Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Int J Obes Relat Metab Disord (1995) 0.79
Statement on postprandial hypoglycemia. Diabetes Care (1988) 0.79
Primary role of glucagon release in the effect of beta-endorphin on glucose homeostasis in normal man. Acta Endocrinol (Copenh) (1987) 0.79
Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa. Clin Nephrol (2009) 0.79
Non oxidative fructose disposal is not inhibited by lipids in humans. Diabetes Metab (1999) 0.79
[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents]. Rev Med Liege (2007) 0.78
Variability of albumin excretion in insulin-dependent diabetics. Diabet Med (1987) 0.78
European Dimension of Diabetes Research. Diabetologia (1996) 0.78
[The epidemic of metabolic diseases, a major problem of public health]. Rev Med Liege (1999) 0.78
The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol (Copenh) (1987) 0.78
[Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?]. Rev Med Liege (2003) 0.78
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Diabetologia (1989) 0.78
[Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]. Rev Med Suisse (2011) 0.78
Intact cross-talk between insulin secretion and insulin action after postgastroplasty recovery of ideal body weight in severely obese patients. Int J Obes Relat Metab Disord (2004) 0.77
Assessment of glucose metabolism in humans with the simultaneous use of indirect calorimetry and tracer techniques. Clin Physiol (1995) 0.77
[Clinical study of the month. Prolonged insulin independence after transplantation of islets of Langerhans in a patient with type 1 diabetes: achievement of a dream?]. Rev Med Liege (2000) 0.77
Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes (1987) 0.77
Assessment of postprandial hepatic glycogen synthesis from uridine diphosphoglucose kinetics in obese and lean non-diabetic subjects. Int J Obes Relat Metab Disord (2000) 0.77
Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement. Diabetes Metab (1996) 0.77
[PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases]. Rev Med Liege (2005) 0.77
Insulin sensitivity in anorexia nervosa: a mirror image of obesity? Diabetes Metab Rev (1988) 0.77
Pulsatile glucagon has greater hyperglycaemic, lipolytic and ketogenic effects than continuous hormone delivery in man: effect of age. Diabetologia (1990) 0.77
Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract (1989) 0.76
Decreased or increased insulin metabolism after glipizide in type II diabetes. Diabetes Care (1988) 0.76
[Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study]. Rev Med Liege (1999) 0.76
[Clinical study of the month. The CAPPP study: "The Captopril Prevention Project"]. Rev Med Liege (1999) 0.76
[Hypercholesterolemia-related cardiovascular risk: a continuum from a notion of normality, intervention threshold and therapeutic objectives]. Rev Med Liege (1999) 0.76
Impaired insulin-induced erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1988) 0.76
Glucose turnover in humans in the basal state and after intravenous glucose: a comparison of two models. Am J Physiol (1997) 0.76
Non-alcoholic steatohepatitis. Lancet (1999) 0.76
Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism. Fertil Steril (1993) 0.76
Utilization of oral sucrose load during exercise in humans. Effect of the alpha-glucosidase inhibitor acarbose. Diabetes (1986) 0.76
Acarbose in reactive hypoglycemia: a double-blind study. Int J Clin Pharmacol Ther Toxicol (1984) 0.76
Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta Clin Belg (1993) 0.76
Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev (2000) 0.76
Autoregulation of endogenous glucose production in man. Biochem Soc Trans (1997) 0.76
Pathogenic tracks in fatigue syndromes. Acta Clin Belg (1994) 0.75
Exogenous glucose oxidation during exercise in relation to the power output. Int J Sports Med (1995) 0.75
[Glucotoxicity and lipotoxicity, two implicated accomplices in the vicious circle of type 2 diabetes]. Rev Med Liege (1999) 0.75
[Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials]. Rev Med Liege (2008) 0.75
[Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes]. Rev Med Suisse (2007) 0.75
Use of 13C substrates for metabolic studies in exercise: methodological considerations. J Appl Physiol (1985) (1991) 0.75
[Metabolically obese normal-weight individuals and metabolically healthy, but obese, subjects]. Rev Med Suisse (2009) 0.75
Influence of the A-->G (-3826) uncoupling protein-1 gene (UCP1) variant on the dynamics of body weight before and after gastroplasty in morbidly obese subjects. Int J Obes Relat Metab Disord (1998) 0.75
U-100 insulin gives some protection against metabolic deterioration due to CSII interruption. Diabetes Care (1988) 0.75
Availability of glucose ingested during muscle exercise performed under acipimox-induced lipolysis blockade. Eur J Appl Physiol Occup Physiol (1994) 0.75
[Type 2 insulin-dependent diabetes: patient characteristics and effects of insulin therapy]. Rev Med Liege (1994) 0.75
Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics. Int J Clin Pharmacol Ther Toxicol (1987) 0.75
Prevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII. Diabetes Care (1988) 0.75
[Syndrome of reactive hypoglycemia. Myth or reality]. Journ Annu Diabetol Hotel Dieu (1983) 0.75
[Transition from insulin U-40 to insulin U-100: the Belgian experience]. Diabete Metab (1993) 0.75
[Opioid peptides and glucose metabolism]. Rev Med Liege (1987) 0.75
Relationships between metabolic clearance rate of insulin and body mass index in a female population ranging from anorexia nervosa to severe obesity. Int J Obes Relat Metab Disord (1994) 0.75
[Viral implications in the etiopathogenesis of type 1 diabetes: current update]. Rev Med Liege (1998) 0.75
Therapy for obesity--today and tomorrow. Baillieres Clin Endocrinol Metab (1994) 0.75